The current study describes a novel next-generation AD therapy that effectively targets multiple aspects of AD’s stochastic pathology by utilizing mechanisms of the GBA potentially through the broad-acting transcriptional regulatory PPARγ (Fig 7). The gene discussed is PPARG; the disease is Alzheimer disease.